press-releases

07 Feb, 2024, 18:48 ET CUPERTINO, Calif., Feb. 7, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually, February 13-14, 2024. Presentation details are as follows: Date and Time:      […]

13 Nov, 2023, 16:05 ET –  Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET –  Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days CUPERTINO, Calif., Nov. 13, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results

09 Nov, 2023, 16:30 ET CUPERTINO, Calif., Nov. 9, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for the three months

07 Nov, 2023, 16:01 ET Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days.  Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg dose compared with standard of care (SOC) Numerical improvement in primary endpoint of mortality or transplant

 07 Sep, 2023, 07:00 ET  Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif., Sept. 7, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that

 31 Aug, 2023, 16:30 ET  CUPERTINO, Calif., Aug. 31, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, will present in the following September 2023 conferences.  H.C.

 09 Aug, 2023, 16:05 ET  –    Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET –    Topline data from AHFIRM trial expected in Q4 2023 CUPERTINO, Calif., Aug. 9, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate

 03 Aug, 2023, 16:30 ET  CUPERTINO, Calif., Aug. 3, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced that the company will report its financial results

 20 Jul, 2023, 08:00 ET  CUPERTINO, Calif., July 20, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) (“DURECT”), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate

 07 Jun, 2023, 06:00 ET  Topline data anticipated in Q4 2023 CUPERTINO, Calif., June 7, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic liver diseases, today announced that it has completed enrollment in its Phase 2b AHFIRM clinical trial (NCT04563026) investigating larsucosterol